Elsevier

The Lancet

Volume 351, Issue 9111, 25 April 1998, Pages 1221-1222
The Lancet

Commentary
Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease

https://doi.org/10.1016/S0140-6736(05)79311-9Get rights and content

References (13)

  • Y Agid et al.

    Tolcapone, bromocriptine, and Parkinson's disease

    Lancet

    (1997)
  • KM Jorga et al.

    Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

    Clin Pharmacol Ther

    (1997)
  • JG Nutt et al.

    Effect of peripheral catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

    Neurology

    (1994)
  • HM Ruottinen et al.

    Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

    J Neurol Neurosurg Psychiatry

    (1996)
  • PT Mannisto et al.

    Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors

    Prog Drug Res

    (1992)
  • RA Hauser ES Molho H Shale et al A pilot evalution of the tolerability, safety, and efficacy of tolcapone alone and in...
There are more references available in the full text version of this article.

Cited by (0)

View full text